Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF

AIM: To estimate the cost‐effectiveness of dapagliflozin added to standard therapy, vs. standard therapy only, in patients with heart failure (HF) with reduced ejection fraction (HFrEF), from the perspective of UK, German, and Spanish payers. METHODS AND RESULTS: A lifetime Markov model was built to...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Eur J Heart Fail
Hoofdauteurs: McEwan, Phil, Darlington, Oliver, McMurray, John J.V., Jhund, Pardeep S., Docherty, Kieran F., Böhm, Michael, Petrie, Mark C., Bergenheim, Klas, Qin, Lei
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Ltd. 2020
Onderwerpen:
Medical Therapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756637/
https://ncbi.nlm.nih.gov/pubmed/32749733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1978
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items